Sanofi and Regeneron's latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche markets, but now looks set to for a toe-to-toe contest with ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Patients in England will be among those who are first to benefit from Sanofi and Regeneron’s new cancer immunotherapy Libtayo, after NICE recommended funding for a form of skin cancer ...

Collaboration revenue from Sanofi increased 22% to $1.21 billion in the fourth quarter, while Bayer collaboration revenue was flat at $377 million. Notably, revenue from cancer drug Libtayo ...

driven by increased demand for Eylea HD (aflibercept 8 mg), Libtayo (cemiplimab), its key medication in the oncology franchise, as well as revenue growth from its collaboration with Sanofi (SNY ...

Total revenues increased 10% year over year to $3.79 billion, fueled by increased collaboration revenues from Sanofi for Dupixent, higher Eylea HD and Libtayo sales. Revenues marginally beat the ...

The article " Regeneron: Is It the Perfect Biotech Stock for Value and Growth? " first appeared on MarketBeat.